Guselkumab is a selective interleukin-23 inhibitor that has been marketed and reimbursed since a few months in Belgium. We conducted a literature review in order to assess the efficacy and safety of guselkumab.
What is already known about the topic?
Guselkumab is a selective interleukin (IL)-23 inhibitor that has been marketed and reimbursed since a few months in Belgium. IL-23 plays a role in the Th17 pathway, which is of key importance in the pathophysiology of psoriasis.
What does this article bring up for us?
This article offers a literature review on the efficacy and safety of guselkumab.
Keywords
Guselkumab, interleukin 23, psoriasis, biotherapy